Modifies provisions relating to alternative therapies

HB 2922 allows manufacturers to provide unapproved investigational drugs, biological products, or devices to patients with terminal, life-threatening, or severely debilitating conditions who have exhausted other FDA-approved treatments. It defines "eligible patients" as those meeting specific medical criteria and requiring physician recommendations and written consent. The bill does not require manufacturers to provide these treatments (they may charge costs), insurers to cover them, or state agencies to penalize doctors for recommending them. It also provides liability protection for providers who follow the law when administering such treatments.